Dec 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AstraZeneca, Confluent and Pepsico, on Tuesday.
HIGHLIGHTS
* AstraZeneca AZN.O: TD Cowen raises target price to $105 from $95 |
* Confluent Inc CFLT.O: Raymond James cuts to market perform from outperform |
* Kymera Therapeutics Inc KYMR.O: Piper Sandler raises target price to $125 from $98 |
* Pepsico PEP.O: Piper Sandler raises target price to $172 from $161 |
* Warner Bros Discovery Inc WBD.O: Seaport Research Partners cuts to neutral from buy |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* Adobe Inc ADBE.O: Stifel cuts target price to $450 from $480 |
* Air Products APD.N: Jefferies cuts target price to $300 from $350 |
* Alexander & Baldwin Inc (Hawaii) ALEX.N: Piper Sandler cuts to neutral from overweight |
* Align Technology ALGN.O: Barclays initiates coverage with equal-weight rating |
* Align Technology ALGN.O: Barclays initiates coverage with target price $170 |
* American Airlines AAL.O: BMO initiates coverage with market perform rating |
* American Airlines AAL.O: BMO initiates coverage with target price $16.75 |
* Amneal Pharmaceuticals AMRX.O: Barclays initiates coverage with target price $15 |
* Amneal Pharmaceuticals AMRX.O: Barclays initiates coverage with overweight rating |
* Amphastar Pharmaceuticals Inc AMPH.O: Barclays initiates coverage with equal weight rating |
* Amphastar Pharmaceuticals Inc AMPH.O: Barclays initiates coverage with target price $30 |
* Ani Pharmaceuticals Inc ANIP.O: Barclays initiates coverage with overweight rating |
* Ani Pharmaceuticals Inc ANIP.O: Barclays initiates coverage with target price $100 |
* Antero Resources Corp AR.N: BMO raises target price to $40 from $37 |
* Antero Resources Corp AR.N: JP Morgan raises target price to $42 from $39 |
* Antero Resources Corp AR.N: Morgan Stanley raises target price to $48.00 from $44.00 |
* Apple Inc AAPL.O: Citigroup raises target price to $330 from $315 |
* Arrowhead Pharmaceuticals ARWR.O: BofA Global Research raises price objective to $81 from $62 |
* AstraZeneca AZN.O: TD Cowen raises target price to $105 from $95 |
* BorgWarner Inc. BWA.N: Wells Fargo cuts target price to $52 from $54 |
* Brightspring Health Services Inc BTSG.O: BofA Global Research raises price objective to $41 from $38 |
* Broadcom Inc AVGO.O: Rosenblatt Securities raises target price to $440 from $400 |
* California Resources Corporation CRC.N: Wells Fargo cuts target price to $56 from $58 |
* Cardinal Health CAH.N: Barclays initiates coverage with overweight rating and PT $243 |
* Cencora COR.N: Barclays initiates coverage with overweight rating and PT $400 |
* Ceribell Inc CBLL.O: TD Cowen raises target price to $29 from $20 |
* Chimera Investment Corp CIM.N: RBC cuts to sector perform from outperform |
* Chimera Investment Corp CIM.N: RBC raises target price to $13 from $6 |
* Ciena Corp CIEN.N: Stifel raises target price to $230 from $152 |
* Colgate-Palmolive Co CL.N: RBC raises to outperform from sector perform |
* Collegium Pharmaceutical Inc. COLL.O: Barclays initiates coverage with overweight rating |
* Collegium Pharmaceutical Inc. COLL.O: Barclays initiates coverage with target price $58 |
* Confluent CFLT.O: Deutsche Bank cuts to hold from buy |
* Confluent CFLT.O: Deutsche Bank raises target price to $31 from $29 |
* Confluent Inc CFLT.O: Canaccord Genuity cuts to hold from buy; ups PT to $31 from $27 |
* Confluent Inc CFLT.O: D.A. Davidson cuts to neutral from buy; raises PT to $31 from $29 |
* Confluent Inc CFLT.O: Deutsche Bank cuts to hold from buy; raises PT to $31 from $29 |
* Confluent Inc CFLT.O: Mizuho cuts to neutral from outperform; ups PT to $31 from $26 |
* Confluent Inc CFLT.O: Needham cuts to hold from buy |
* Confluent Inc CFLT.O: Oppenheimer cuts to perform from outperform |
* Confluent Inc CFLT.O: Raymond James cuts to market perform from outperform |
* Confluent Inc CFLT.O: RBC cuts to sector perform from outperform |
* Confluent Inc CFLT.O: RBC raises target price to $31 from $30 |
* Confluent Inc CFLT.O: Stephens cuts to equal-weight from overweight |
* Confluent Inc CFLT.O: Stephens raises target price to $31 from $29 |
* Confluent Inc CFLT.O: TD Cowen raises target price to $31 from $27 |
* Confluent Inc CFLT.O: Truist Securities cuts to hold from buy; ups PT to $31 from $29 |
* Confluent Inc CFLT.O: UBS cuts to neutral from buy |
* Confluent Inc CFLT.O: UBS raises target price to $31 from $29 |
* Confluent Inc CFLT.O: Wells Fargo cuts to equal weight from overweight |
* Confluent Inc CFLT.O: Wells Fargo raises target price to $31 from $30 |
* Cross Country Healthcare Inc CCRN.O: UBS cuts target price to $9 from $16.5 |
* Cullinan Therapeutics Inc CGEM.O: Wedbush raises target price to $34 from $25 |
* Dana Incorporated DAN.N: Wells Fargo raises target price to $23 from $21 |
* Deere & Co DE.N: Jefferies raises target price to $475 from $440 |
* Definitive Healthcare Corp DH.O: Barclays cuts target price to $2.75 from $3 |
* Delta Air Lines Inc DAL.N: BMO initiates coverage with outperform rating; PT $80 |
* Dentsply Sirona XRAY.O: Barclays initiates coverage with underweight rating and PT $12 |
* Dollar Tree Inc DLTR.O: Barclays raises target price to $136 from $120 |
* Doximity DOCS.N: Barclays initiates coverage with overweight rating and PT $63 |
* Dyne Therapeutics Inc DYN.O: Bernstein raises target price to $23 from $21 |
* Dyne Therapeutics Inc DYN.O: Morgan Stanley raises target price to $50.00 from $46.00 |
* Elanco Animal Health Inc. ELAN.N: Barclays initiates coverage with overweight rating |
* Elanco Animal Health Inc. ELAN.N: Barclays initiates coverage with target price $30 |
* Envista Holdings Corp. NVST.N: Barclays initiates coverage with overweight rating |
* Envista Holdings Corp. NVST.N: Barclays initiates coverage with target price $24 |
* FMC Corp. FMC.N: Barclays cuts target price to $13 from $16 |
* FMC Corp. FMC.N: Barclays cuts to underweight from equal-weight |
* Galaxy Digital Inc GLXY.O: Citizens initiates coverage with market outperform rating |
* Galaxy Digital Inc GLXY.O: Citizens initiates coverage with target price $60 |
* General Motors Co. GM.N: Wells Fargo raises target price to $48 from $46 |
* Glaukos Corp GKOS.N: Needham raises target price to $125 from $117 |
* Goodrx Holdings Inc. GDRX.O: Barclays initiates coverage with target price $3 |
* Goodrx Holdings Inc. GDRX.O: Barclays initiates coverage with underweight rating |
* Graphic Packaging Holding Co GPK.N: Baird cuts target price to $18 from $24 |
* Healthequity HQY.O: Barclays initiates coverage with overweight rating and PT $118 |
* Henry Schein HSIC.O: Barclays initiates coverage with overweight rating and PT $86 |
* Hims & Hers Health HIMS.N: Barclays initiates coverage with overweight rating |
* Hims & Hers Health HIMS.N: Barclays initiates coverage with target price $48 |
* Hormel Foods Corp. HRL.N: Barclays cuts target price to $30 from $31 |
* IBM IBM.N: Stifel raises target price to $325 from $295 |
* Idexx Laboratories, Inc. IDXX.O: Barclays initiates coverage with overweight rating |
* Idexx Laboratories, Inc. IDXX.O: Barclays initiates coverage with target price $850 |
* Immix Biopharma, Inc. IMMX.O: H.C. Wainwright raises target price to $12 from $8 |
* Ionis Pharmaceuticals IONS.O: BofA Global Research ups price objective to $97 from $86 |
* Jack In the Box Inc JACK.O: RBC raises target price to $25 from $16 |
* Keycorp KEY.N: Piper Sandler raises target price to $22 from $20 |
* Kroger Co KR.N: Citigroup cuts target price to $68 from $74 |
* Kymera Therapeutics KYMR.O: Barclays raises target price to $119 from $70 |
* Kymera Therapeutics KYMR.O: Oppenheimer raises target price to $120 from $67 |
* Kymera Therapeutics Inc KYMR.O: BofA Global Research ups price objective to $112 from $71 |
* Kymera Therapeutics Inc KYMR.O: BTIG raises target price to $138 from $75 |
* Kymera Therapeutics Inc KYMR.O: H.C. Wainwright raises target price to $134 from $84 |
* Kymera Therapeutics Inc KYMR.O: Morgan Stanley raises target price to $127.00 from $73.00 |
* Kymera Therapeutics Inc KYMR.O: Piper Sandler raises target price to $125 from $98 |
* Kymera Therapeutics Inc KYMR.O: Truist Securities raises target price to $116 from $80 |
* Kymera Therapeutics Inc KYMR.O: Wells Fargo raises target price to $116 from $69 |
* Lear Corporation LEA.N: Wells Fargo cuts target price to $107 from $112 |
* Lifestance Health Group Inc LFST.O: Barclays initiates coverage with overweight rating |
* Lifestance Health Group Inc LFST.O: Barclays initiates coverage with target price $8 |
* Ligand Pharmaceuticals Inc LGND.O: Citigroup initiates coverage with buy rating |
* Ligand Pharmaceuticals Inc LGND.O: Citigroup initiates coverage with price target $270 |
* Lyell Immunopharma Inc LYEL.O: H.C. Wainwright raises target price to $45 from $20 |
* Lyell Immunopharma Inc LYEL.O: H.C. Wainwright raises to buy from neutral |
* Lyft, Inc. LYFT.O: Wells Fargo raises target price to $26 from $20 |
* Mannkind Corp MNKD.O: Leerink Partners raises target price to $9 from $7 |
* McKesson MCK.N: Barclays initiates coverage with overweight rating and PT $960 |
* Micron Technology Inc MU.O: Bernstein raises target price to $270 from $170 |
* Mirum Pharmaceuticals MIRM.O: Morgan Stanley raises target price to $95.00 from $81.00 |
* Mosaic MOS.N: Barclays cuts target price to $31 from $35 |
* $Nextera Energy Inc(NEE-N)$ NEE.N: BTIG raises target price to $100 from $98 |
* Nike Inc NKE.N: Citigroup cuts target price to $70 from $74 |
* NRG Energy Inc NRG.N: UBS initiates coverage with buy rating and target price $211 |
* Nurix Therapeutics Inc NRIX.O: BTIG raises target price to $30 from $27 |
* Omnicell Inc OMCL.O: Benchmark raises target price to $50 from $45 |
* Option Care Health OPCH.O: Deutsche Bank raises target price to $36 from $31 |
* Option Care Health Inc OPCH.O: BofA Global Research ups price objective to $35 from $32 |
* Oracle Corp. ORCL.N: Barclays cuts target price to $330 from $400 |
* Organon OGN.N: Barclays initiates coverage with underweight rating and PT $7.5 |
* Otis Worldwide Corp OTIS.N: Exane BNP Paribas raises to outperform from neutral |
* Pacira Biosciences PCRX.O: Barclays initiates coverage with equal-weight rating |
* Pacira Biosciences PCRX.O: Barclays initiates coverage with target price $27 |
* Paramount Skydance Corporation PSKY.O: Morgan Stanley raises target to $12.00 from $10.00 |
* Paychex Inc PAYX.O: BMO cuts target price to $121 from $140 |
* Paychex, Inc. PAYX.O: Wells Fargo cuts target price to $116 from $128 |
* PayPal Holdings, Inc. PYPL.O: Wells Fargo cuts target price to $67 from $74 |
* Penske Automotive Group PAG.N: BofA Global Research reinstates with buy rating |
* Penske Automotive Group PAG.N: BofA Global Research reinstates with price objective $195 |
* Peoples Financial Services Corp PFIS.O: Stephens cuts to equal-weight from overweight |
* Pepsico PEP.O: Jefferies raises target price to $164 from $163 |
* Pepsico PEP.O: Piper Sandler raises target price to $172 from $161 |
* Phathom Pharmaceuticals Inc. PHAT.O: Barclays initiates coverage with equal-weight rating |
* Phathom Pharmaceuticals Inc. PHAT.O: Barclays initiates coverage with target price $16 |
* Phreesia PHR.N: Barclays initiates coverage with overweight rating and PT $26 |
* Pilgrim'S Pride Corp PPC.O: Barclays cuts target price to $45 from $49 |
* Planet Fitness Inc PLNT.N: RBC raises target price to $135 from $120 |
* Progressive Corp PGR.N: BMO cuts target price to $256 from $260 |
* Progressive Corp PGR.N: BofA Global Research cuts price objective to $348 from $350 |
* Progyny PGNY.O: Barclays initiates coverage with overweight rating and PT $29 |
* Pseg PEG.N: BofA Global Research adds stock to its US 1 list |
* Rapport Therapeutics, Inc. RAPP.O: H.C. Wainwright raises target price to $40 from $34 |
* RPM International Inc RPM.N: RBC raises target price to $132 from $121 |
* RPM International Inc RPM.N: RBC raises to outperform from sector perform |
* Sarepta Therapeutics Inc SRPT.O: Wedbush initiates coverage with outperform rating |
* Sarepta Therapeutics Inc SRPT.O: Wedbush initiates coverage with target price $32 |
* SL Green Realty Corp SLG.N: Deutsche Bank cuts target price to $46 from $60 |
* SLM Corp SLM.O: Morgan Stanley cuts target price to $31.00 from $36.00 |
* SLM Corp SLM.O: Morgan Stanley cuts to equal-weight from overweight |
* Southwest Airlines Co LUV.N: BMO initiates coverage with market perform rating; PT $43 |
* Southwest Gas Holdings Inc SWX.N: Jefferies cuts target price to $89 from $92 |
* Structure Therapeutics Inc GPCR.O: Citigroup raises target price to $100 from $60 |
* Synopsys Inc SNPS.O: Rosenblatt Securities cuts target price to $560 from $605 |
* Synopsys Inc SNPS.O: Rosenblatt Securities raises to buy from neutral |
* Talkspace TALK.O: Barclays initiates coverage with equal-weight rating and PT $3.5 |
* Tarsus Pharmaceuticals TARS.O: Barclays initiates coverage with overweight rating |
* Tarsus Pharmaceuticals TARS.O: Barclays initiates coverage with target price $100 |
* Teladoc Health TDOC.N: Barclays initiates coverage with target price $8.5 |
* Teladoc Health TDOC.N: Barclays initiates coverage with equal-weight rating |
* Terns Pharmaceuticals TERN.O: Barclays raises target price to $56 from $36 |
* Terns Pharmaceuticals Inc TERN.O: BMO raises target price to $54 from $35 |
* Terns Pharmaceuticals Inc TERN.O: H.C. Wainwright raises target price to $60 from $20 |
* Terns Pharmaceuticals Inc TERN.O: Mizuho raises target price to $54 from $33 |
* Terns Pharmaceuticals Inc TERN.O: Oppenheimer raises target price to $58 from $28 |
* Terns Pharmaceuticals Inc TERN.O: Oppenheimer raises target price to $58 from $28 |
* Terns Pharmaceuticals Inc TERN.O: Truist Securities raises target price to $56 from $35 |
* Thor Industries Inc THO.N: Truist Securities raises target price to $112 from $110 |
* Truist Financial Corp TFC.N: Piper Sandler raises target price to $50 from $48 |
* Tyler Technologies Inc TYL.N: D.A. Davidson cuts target price to $510 from $540 |
* United Airlines UAL.O: BMO initiates coverage with outperform rating; target price $125 |
* Vail Resorts MTN.N: Deutsche Bank raises target price to $162 from $159 |
* Viatris Inc. VTRS.O: Barclays initiates coverage with overweight rating and PT $15 |
* Visteon Corp. VC.O: Wells Fargo cuts target price to $148 from $151 |
* Vor Biopharma Inc VOR.O: JP Morgan initiates coverage with overweight rating; PT $43 |
* Warner Bros Discovery Inc WBD.O: Deutsche Bank raises target price to $29.50 from $26 |
* Warner Bros Discovery Inc WBD.O: Seaport Research Partners cuts to neutral from buy |
* Waystar Holding Corp. WAY.O: Barclays cuts target price to $42 from $50 |
* Wells Fargo WFC.N: Piper Sandler raises target price to $100 from $93 |
* Weyerhaeuser Co WY.N: CIBC cuts target price to $27 from $30 |
* Wingstop Inc WING.O: RBC raises target price to $350 from $300 |
* Wynn Resorts Ltd WYNN.O: BofA Global Research raises price objective to $150 from $140 |
* Xeris Biopharma Holdings Inc. XERS.O: Barclays initiates coverage with overweight rating |
* Xeris Biopharma Holdings Inc. XERS.O: Barclays initiates coverage with target price $9 |
* Zoetis Inc. ZTS.N: Barclays initiates coverage with equal-weight rating and PT $136 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))